Lyell Immunopharma Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing next-generation CAR T-cell therapies, with ronde-cel showing high response rates and a favorable safety profile in pivotal trials. Manufacturing is fully in-house, and commercial launch is targeted for next year. LYL273 for solid tumors is also progressing, with promising early data and upcoming disclosures.
-
Multiple pivotal trials are advancing for next-generation CAR T-cell therapies in lymphoma and colorectal cancer, with strong early efficacy and safety data. Major data updates are expected in H2, and financial resources are secured for continued development.
-
Key updates include a new CFO hire, a $50M financing milestone, and strong clinical progress for the dual-targeted ronde-cel CAR T-cell therapy, which shows high response rates and a favorable safety profile. The company is also advancing a novel GCC CAR T-cell program for solid tumors, with promising early data and upcoming readouts.
-
Significant clinical progress was highlighted for dual-targeting CAR T-cell therapies in lymphoma and colorectal cancer, with pivotal trials underway and promising early efficacy and safety data. Scalable manufacturing and a strong cash position support upcoming milestones through 2027.
Fiscal Year 2025
-
Ronde-cel demonstrated high response and durable remission rates in high-risk large B-cell lymphoma patients, with a favorable safety profile and strong translational data supporting its mechanism. LYL273 showed promising efficacy in metastatic colorectal cancer, with manageable safety and innovative design.
-
Exclusive global rights to LYL273, a next-gen CAR T-cell therapy for metastatic colorectal cancer, were acquired, showing a 67% response rate in phase I U.S. trials and strong potential in a large, underserved market. Optimized safety protocols and robust manufacturing support rapid development.
-
RondaCell, a dual-targeting CD19/20 CAR T therapy, is showing superior response and safety compared to current CD19 CARs, with pivotal trials in both third- and second-line lymphoma settings. Key data updates are expected by year-end, supporting its potential to disrupt the market.
-
RONDACELL, a dual-targeting CD19/CD20 CAR T therapy, is advancing through pivotal trials for large B-cell lymphoma, showing high response rates and a favorable safety profile. The company is leveraging in-house manufacturing, strong IP, and a robust financial position to pursue both hematologic and solid tumor indications, with a BLA filing targeted for 2027.
-
The conference highlighted strong clinical data for a dual-targeting CD19/20 CAR T-cell therapy, showing higher response and durability rates than current CD19 CARs, with a favorable safety profile and broad patient eligibility. Regulatory progress and a robust competitive position support a strategy targeting both third- and second-line lymphoma settings.
-
The team is advancing a dual-targeting CAR T-cell therapy for large B-cell lymphoma, now in pivotal trials with strong early efficacy and a clear FDA pathway. Manufacturing and commercial infrastructure are in place, and the pipeline includes next-gen solid tumor programs.
-
Next-generation CAR T-cell therapies are advancing toward pivotal trials in 2025, targeting both second- and third-line aggressive large B-cell lymphoma with promising early efficacy and safety data. A strong balance sheet, commercial-ready manufacturing, and a robust pipeline support multi-billion dollar market ambitions.
-
IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy, is advancing to pivotal trials for aggressive large B-cell lymphoma, showing high response rates and a favorable safety profile. The company is also developing next-generation CAR T-cell therapies for solid tumors, with strong financials supporting clinical milestones into 2027.
-
The conference highlighted strong Phase I results for a dual-targeting CD19/CD20 CAR T therapy, with pivotal trials set for 2025 and 2026. Proprietary technologies and robust financials support ongoing innovation in both hematologic and solid tumor indications.
Fiscal Year 2024
-
The acquisition brings a dual-targeting CD19/CD20 CAR T-cell candidate with strong phase 1 data into the pipeline, aiming to address unmet needs in aggressive B-cell lymphoma. The deal includes $30M cash, stock, and milestones, and is expected to accelerate clinical development and market entry, with pivotal trials planned for 2025.
-
Lead CAR T program showed 40% response and 60% benefit in phase I, with expansion to more tumor types. Next-gen CAR T and TIL programs are advancing, with key data and IND filings expected in 2024. Strong cash position supports milestones into 2027.
-
The company presented strong clinical progress for its ROR1 CAR T and TIL programs, highlighting dose-dependent efficacy, manageable safety, and expansion into new indications. Proprietary anti-exhaustion technologies and robust manufacturing underpin a pipeline with significant near-term milestones and financial runway into 2027.
-
Initial phase I data for LYL797 show dose-dependent clinical activity and robust CAR T-cell tumor infiltration, with a 40% objective response rate at 150 million cells and manageable safety profile. Translational data validate anti-exhaustion technologies, and further dose escalation and expansion into new indications are underway.
-
Proprietary T cell reprogramming technologies are advancing in phase 1 trials for solid tumors, with key data from LYL797 expected by end of June. Preclinical and translational benchmarks support a robust pipeline, and strong cash reserves enable progress into 2027.